Success Metrics

Clinical Success Rate

92.7%

Based on 51 completed trials

Completion Rate

93%(51/55)

Active Trials

1(2%)

Results Posted

47%(24 trials)

Terminated

4(7%)

Phase Distribution

Ph phase_3

25%

Ph phase_4

29%

Ph phase_1

Ph not_applicable

15%

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution57 total trials

Phase 1Safety & dosage

4(7.0%)

Phase 2Efficacy & side effects

12(21.1%)

Phase 3Large-scale testing

15(26.3%)

Phase 4Post-market surveillance

17(29.8%)

N/ANon-phased studies

9(15.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.7%

51 of 55 finished

Non-Completion Rate

7.3%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(51)

Terminated(4)

Other(3)

Detailed Status

Completed51

Terminated4

unknown2

Recruiting1

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

92.7%

Most Advanced

Phase 4

Trials by Phase

Phase 14 (7.0%)

Phase 212 (21.1%)

Phase 315 (26.3%)

Phase 417 (29.8%)

N/A9 (15.8%)

Trials by Status

unknown23%

completed5186%

recruiting12%

suspended12%

terminated47%

Recent Activity

1 active trials

Showing 5 of 59

recruitingnot_applicable

Salmeterol Effect on Exercise Performance

NCT06655012

completedphase_3

A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.

NCT00274560

terminatedphase_3

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772

terminatedphase_3

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00662740

completed

Replication of the POET-COPD Trial in Healthcare Claims Data

NCT05083429

View all 59 trials

Clinical Trials (59)

Showing 20 of 59 trialsScroll for more

NCT06655012Not Applicable

Salmeterol Effect on Exercise Performance

Recruiting

NCT00274560Phase 3

A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.

Completed

NCT00668772Phase 3

Tiotropium/Salmeterol Inhalation Powder in COPD

Terminated

NCT00662740Phase 3

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Terminated

NCT05083429

Replication of the POET-COPD Trial in Healthcare Claims Data

Completed

NCT02232087Phase 1

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Completed

NCT03240575Phase 4

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Completed

NCT01388595Phase 4

Fluticasone and Salmeterol in Allergic Rhinitis

Completed

NCT03055988Phase 4

Cardiovascular Function in COPD Patients

Completed

NCT01892787Phase 4

Effects of Particle Size in Small Airways Dysfunction

Completed

NCT00808288Phase 2

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

Completed

NCT02446418Phase 3

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Completed

NCT02172794Phase 3

Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)

Completed

NCT00984659Phase 4

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Completed

NCT01290874Phase 3

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)

Completed

NCT00200967Phase 3

Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)

Completed

NCT00214019Not Applicable

The Effect of Salmeterol on Eosinophil (EOS) Function

Completed

NCT00364273Phase 1

GSK159802 In Healthy Male Subjects And Asthmatics

Completed

NCT00595361Not Applicable

How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment

Completed

NCT00706446Not Applicable

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

Terminated

Drug Details

Intervention Type: DRUG
Total Trials: 59